InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,098.02
(
0.24%
)
Dow Jones
39,357.01
(
0.00%
)
Brent Oil
81.46
(
-0.18%
)
Bitcoin
58,890.97
(
-0.78%
)
Post# of 252864
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 60
Posts 11554
Boards Moderated 0
Alias Born 07/16/2006

jbog

Member Level

Re: DewDiligence post# 119748

Tuesday, 05/10/2011 2:00:37 PM

Tuesday, May 10, 2011 2:00:37 PM

Post# of 252864

Woodcock said that if a biotech company develops a longer-lasting version of a drug, or otherwise alters an existing molecule to improve efficacy of safety, it would be considered a new molecule, with a new 12-year exclusivity.



This seems like it will open a new bag of worms. Betterbiosimilar.

I'm wondering how they would treat something like Lilly's humanized egfr versus the chimeric cetuximab?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up